1. In Vivo
  2. >>Manufacturing Focus

Supply Chain Pressures No Excuse For Poor Quality Management

 
• By Kelly Stanton

Drug manufacturers have been feeling the crunch from global supply chain issues, but the FDA will accept no excuses when it comes to quality and safety. How can manufacturers prepare for proposed changes to quality measurement requirements?  

Supplychain
Years into the pandemic the global supply chain is on the verge of breaking apart • Source: Shutterstock

Two and a half years into the pandemic, the global supply chain is on the verge of breaking apart. From cars and computer chips to baby formula and pet food, the products we rely upon for our everyday lives are coming up short on our shelves.

The drug manufacturing industry hasn’t been immune to production delays due to COVID-19 shutdowns, shipping bottlenecks, and labor shortages. As...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing Focus

Rising Leaders 2025: How Christina Smolke Turned Research Into Real World Impact

 
• By David Wild

The Stanford professor-turned-CEO's 15-year journey demonstrates how scientific vision and focused leadership can revolutionize pharmaceutical supply chains.

Future Proofing Gene Therapy Assays For Regulatory Success

 
• By Deborah Phippard

As gene therapy advances and regulations tighten, biopharma companies face growing pressure to design diagnostic assays that are both flexible and future ready. Strategic early investment in assay development can prevent costly delays and rework as therapies progress toward approval.

CRL Trio Brings Shifting Sand To Regenerative Medicine Regulation

 
• By Bridget Silverman

Replimune's RP1 oncolytic immunotherapy became the third regenerative medicine to receive an FDA complete response letter this month as the agency appears to re-visit previous agreements about accelerated approval.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By David Wild

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.

More from In Vivo

Deals Shaping The Industry, July 2025

An interactive look at pharma, medtech and diagnostics deals made during July 2025. Data courtesy of Biomedtracker.

By The Numbers: Phase III Trials In China Skyrocket While Phase I Falls To Earth

 
• By Mainbayar Badarch

China has rapidly expanded its clinical trial footprint since 2015, driven by regulatory reforms and increased investment in pharma R&D. By 2023, it matched the US in trial volume. Oncology leads, but biologics are leading in momentum.

Pharma’s Space Trails Entering Transformative Era

 
• By Anju Ghangurde

Merck and Lilly are among the leading pharma players using space-based research to power drug development. From reusable satellites to process drugs in low earth orbit to biomanufacturing labs experts discuss R&D opportunities in the starry canvas above.